Italia markets close in 43 minutes
FTSE MIB
33.531,98 -175,23 (-0,52%) Dow Jones
38.995,26 -116,90 (-0,30%) Nasdaq
17.776,41 +58,76 (+0,33%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
80,64 -0,19 (-0,24%) Bitcoin EUR
57.738,36 -64,85 (-0,11%)
NBIX Mar 2025 170.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:40PM EDT. Mercato aperto.
| Chiusura precedente | 7,90 |
| Aperto | N/D |
| Denaro | 6,70 |
| Domanda | 9,90 |
| Prezzo d'esercizio | 170,00 |
| Scadenza | 2025-03-21 |
| Min-Max giorno | 7,90 - 7,90 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.